Paysign, Inc. - Common Stock (PAYS)

Patient programs drove margin gains, but a plasma client's departure looms in Q4.

Paysign (NASDAQ:PAYS) reported record third-quarter revenue, operating income and adjusted EBITDA as growth in its patient affordability business more than offset slower growth in plasma payment processing. Revenue rose 42.6% from a year earlier to $30.8 million, while net income climbed to $6.7 mi

Paysign (NASDAQ:PAYS) operates in two healthcare-focused businesses: payment services for plasma donors and pharmaceutical patient-affordability programs, Chief Financial Officer Jeff Baker said during a company presentation. Baker described the company as both a payments and life sciences business

Paysign (NASDAQ:PAYS) reported record second-quarter revenue, net income and adjusted EBITDA for 2026, driven primarily by continued expansion in its Patient Affordability business and improving utilization in its plasma donor compensation operations. Revenue rose 48.1% from a year earlier to $28.3

Paysign PAYS Q1 2026 Earnings Call Transcript

Paysign handily beat Wall Street analysts in the first quarter but didn't raise guidance. The stock looks cheap.

Paysign (NASDAQ:PAYS) reported what executives described as the strongest start to a year in the company’s history, with first-quarter 2026 revenue rising 50.8% year over year to $28 million and profitability expanding sharply as its patient affordability business became its largest revenue contribu